Sickle Cell Disease (SCD) Treatment in Turkey
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is a Sickle Cell Disease (SCD)?
Sickle cell disease (SCD) is a group of inherited blood disorders caused by abnormal haemoglobin, most commonly haemoglobin S. This abnormal haemoglobin can make red blood cells rigid and sickle-shaped, making them more likely to break down early and block small blood vessels. This can lead to anaemia, painful vaso-occlusive crises and progressive damage to organs such as the lungs, kidneys, brain, bones and spleen. SCD is inherited when a child receives disease-causing haemoglobin variants from their parents.
What is the Importance of Timely Treatment?
Timely diagnosis and comprehensive treatment can help reduce painful crises, prevent complications and protect organ function. Regular monitoring allows doctors to identify anaemia, infection, stroke risk, kidney problems, eye complications and other effects of SCD at an earlier stage. Disease-modifying medicines, transfusion programmes, vaccination and preventive care can reduce complications, while selected patients with severe disease may be evaluated for hematopoietic stem-cell transplantation or gene therapy.
What are the Common Symptoms of Sickle Cell Disease (SCD)?
- Episodes of severe pain, known as vaso-occlusive crises
- Chronic or recurrent anaemia
- Fatigue and weakness
- Shortness of breath
- Pale skin or yellowing of the eyes
- Swelling of the hands and feet, particularly in young children
- Frequent infections
- Delayed growth or puberty in some children
- Bone and joint pain
- Abdominal pain
- Vision problems
- Symptoms related to stroke or neurological complications
- Priapism in some males
- Chronic organ-related complications in severe disease
Causes and Risk Factors of Sickle Cell Disease (SCD)
Causes
- Sickle cell disease results from inherited changes in the HBB gene, which provides instructions for producing beta-globin, a component of haemoglobin.
- Different combinations of abnormal haemoglobin genes can produce different forms of SCD.
- The most severe and common form, HbSS, generally occurs when a child inherits a sickle haemoglobin gene from both parents.
Risk Factors
- Having parents who carry sickle haemoglobin or another disease-causing haemoglobin variant
- Family history of sickle cell disease
- Inheriting two disease-causing haemoglobin variants
- Genetic ancestry associated with a higher prevalence of sickle haemoglobin, including parts of Africa, the Middle East, the Mediterranean, South Asia and other regions
- Lack of access to early screening and comprehensive SCD care, which can increase the risk of preventable complications
Latest Research and Technologies in the Treatment of Sickle Cell Disease (SCD) in Turkey
- Sickle cell treatment is increasingly moving toward disease-modifying and potentially curative approaches. Hydroxyurea remains an important therapy to reduce sickling and complications, while blood transfusion programmes are used in selected patients. Hematopoietic stem-cell transplantation can provide a potential cure for appropriately selected patients, particularly those with severe disease and a suitable donor. Gene therapies have introduced another potential curative approach. These therapies require specialised cell collection, conditioning treatment and long-term monitoring and are currently intended for carefully selected patients.
Treatment options for Sickle Cell Disease (SCD)
Blood Transfusion Therapy: Red blood-cell transfusions may treat severe anaemia or prevent or manage selected complications, such as stroke. Long-term transfusion programmes require monitoring for iron overload and other transfusion-related complications.
Stem-Cell Transplantation : Allogeneic hematopoietic stem-cell transplantation can potentially cure SCD in selected patients. Suitability depends on factors such as disease severity, organ health, age, donor availability and the risks associated with transplantation.
Cost Start From 20000Explore Options
Gene Therapy: Selected patients with severe SCD may be evaluated for autologous gene-based therapies. These approaches involve collecting the patient's own blood-forming stem cells, modifying them in a specialised laboratory and returning them after conditioning treatment.
- Clinical assessment:
- Medical and Haematological Evaluation: A detailed history is taken to assess pain crises, fatigue, anemia, infections, transfusion history, jaundice, breathing problems, neurological symptoms, vision changes, bone complications and other SCD-related symptoms.
- Complete Blood Count and Peripheral Blood Assessment: A complete blood count evaluates hemoglobin, red blood cells, white blood cells, and platelets. A peripheral blood smear can show red-cell morphology and other blood abnormalities associated with SCD.
- Hemoglobin Analysis: Hemoglobin electrophoresis, high-performance liquid chromatography or other specialised testing can identify abnormal hemoglobin types and help determine the specific SCD genotype or hemoglobinopathy.
- Assessment of Organ Complications: Depending on age and symptoms, evaluation may include kidney function and urine testing, liver assessment, pulmonary evaluation, eye examination and neurological assessment.
- Genetic and Family Assessment: Genetic counselling and testing may help clarify the inherited hemoglobin pattern and provide information about reproductive risks and family screening.
- Imaging Tests:
- Transcranial Doppler Ultrasound: Used particularly in children with SCD to assess cerebral blood-flow velocities and help identify increased stroke risk.
- Brain MRI and MRA: May be recommended when neurological symptoms, previous stroke or silent cerebral injury is suspected.
- Chest X-ray: May be used when acute chest syndrome, pneumonia or another chest complication is suspected.
- Echocardiography: May be used to evaluate cardiac structure and function when clinically indicated.
- Ultrasound or MRI: May help evaluate abdominal, bone, or other organ complications depending on symptoms.
- Retinal Imaging: Ophthalmologic imaging can detect sickle-cell-related retinal changes.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive tele-rehabilitation services designed to support Sickle Cell Disease (SCD) patients in Turkey. These services include:
- Physical Activity and Exercise: Individualised physical activity can help maintain strength, mobility and cardiovascular fitness, with intensity adjusted according to anemia, pain, organ complications and overall health.
- Pain and Mobility Rehabilitation: Physiotherapy may help patients manage chronic musculoskeletal pain, maintain joint mobility and improve functional movement while avoiding activities that worsen symptoms.
- Fatigue and Energy Management: Structured activity planning, appropriate rest, sleep support and treatment of underlying anemia can help patients manage chronic fatigue and maintain daily activities.
- Psychological and Self-Management Support: Counselling, patient education and chronic-pain support can help patients cope with recurrent crises, treatment demands, school or work limitations and the emotional effects of living with a chronic blood disorder.
- Medicines for SCD aim to reduce sickling, prevent complications and manage acute symptoms. Hydroxyurea is an established disease-modifying medicine that can increase fetal hemoglobin and reduce the frequency of pain crises in appropriate patients. Other medicines may be used for pain management and selected disease-related complications. Pain-relief medicines are used during crises, while patients receiving repeated transfusions may need monitoring and treatment for iron overload. Regular follow-up helps assess treatment response and identify adverse effects.
Instantly Connect with our Specialists
Hospitals for Sickle Cell Disease (SCD) in Turkey
Medipol Bahçelievler Hospital
Istanbul, Turkey
Medipol Bahcelievler Hospital is a medical institution providing a full range of medical and individualized approaches to its patients. Medipol has the ambition to bring high quality and maximum security to people in need by employing state-of-the-art technologies in medicine. They ensure that the health of the patients is improved by fashioning unique physician specialty treatment programs.
Medipol Bahcelievler Hospital provides an exceptional position in the healthcare industry with a policy of clear communication, professionalism, and reliability to patient expectations. Medipol Bahçelievler Hospital is situated in the European Side of Istanbul, dedicated to 24-hour health care for you and your loved ones, equipped with a fully functional operation theatre and ICUs with state-of-the-art equipment, laboratory, emergency, and advanced treatment rooms
Baskent University Istanbul Hospital
Istanbul, Turkey
Baskent University Istanbul Hospital located in Istanbul, Turkey is accredited by ISO. Also listed below are some of the most prominent infrastructural details:
- 13.000 square meters indoor area
- Aesthetically designed Inpatient rooms
- Latest healthcare equipments
- 105 bed capacity
- 5 operating rooms
- 38 bed capacity in the Intensive Care Unit
- 609 healthcare personnel and healthcare professors
- Translation services for International patients
Asya Hospital
Istanbul, Turkey
Apart from in-detail treatment procedures available, Asya Hospital located in Istanbul, Turkey has a wide variety of facilities available for International Patients. Some of the facilities which are provided by them are Accommodation, Airport Transfer, Choice of Meals, Interpreter, SIM, TV inside room. Also listed below are some of the most prominent infrastructural details:
- 75 bed capacity
- Rooms for different requirements are present: 4 suites, 30 patient rooms
- 10 Adult Intensive Care Units
- 35 Newborn Intensive Care Units
- Facilities Provided: Accommodation, Choice of Meals, Interpreter, SIM, TV inside room
- International patient care center: Flight Booking, Airport Transfer
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose Turkey for Sickle Cell Disease (SCD) Treatment?
- Multidisciplinary Hematology Care: Patients can access hematologists, pediatric hematologists, transfusion specialists, genetic counsellors and other specialists according to their needs.
- Advanced Diagnostic Facilities: Specialised centres may provide hemoglobin analysis, genetic testing, blood-count monitoring, organ-function assessment and imaging for SCD-related complications.
- Comprehensive Disease Management: Treatment can include hydroxyurea, pain management, transfusion programmes, vaccination and monitoring for organ complications.
- Stem-Cell Transplantation: Major transplant centres can evaluate eligible patients for allogeneic hematopoietic stem-cell transplantation and provide donor assessment and post-transplant monitoring.
- Advanced Cellular and Gene-Based Therapies: Specialised centres may provide access to emerging cellular or gene-based treatment programmes where regulatory approval, clinical eligibility and infrastructure permit.
Frequently Asked Questions
Reviewer
Dr. Akash Khandelwal
Hematologist
9 Years of Experience
Dr. Akash Khandelwal is a distinguished Hematologist, Hemato-oncologist, and Bone Marrow Transplant (BMT) Physician with extensive training from the prestigious AIIMS New Delhi. His expertise encompasses a wide range of specialized techniques in bone marrow transplantation, including autologous and allogeneic transplants such as matched sibling donors, matched unrelated donors (MUD), and haploidentical donor transplants. Dr. Khandelwal has personally supervised and conducted over 100 bone marrow transplants. View More
Last Reviewed - January 2026